Efficacy and safety of anisodamine as adjuvant therapy in septic shock: a systematic review and meta-analysis
Wirksamkeit und Sicherheit von Anisodamin als adjuvante Therapie beim septischen Schock: systematische Übersichtsarbeit und Metaanalyse
Frontiers in Pharmacology · 30.10.2026 · 17
DOI: 10.3389/fphar.2026.1976742 ↗Auf einen Blick
14 RCTs zeigen: Anisodamin war mit geringerer 28-Tage-Mortalität und besseren hämodynamischen sowie Stoffwechselparametern verbunden. Die Sicherheitsdaten waren unzureichend.
Fragestellung
Wie wirksam und sicher ist Anisodamin als adjuvante Therapie beim septischen Schock?
Methode
Systematische Suche in PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science, CNKI, Wanfang Data und VIP bis 1. Juni 2026; Einschluss von RCTs; Bias- und GRADE-Bewertung.
Ergebnisse
14 RCTs (2 auf Englisch, 12 auf Chinesisch). 28-Tage-Mortalität in 6 Studien niedriger: RR 0,76 (95 %-KI 0,62–0,93). Zudem höhere MAP, höherer SVRI, höhere Lactat-Clearance und niedrigere SOFA- sowie APACHE-II-Scores.
Einschränkungen
Unerwünschte Ereignisse wurden unzureichend berichtet; kardiale Sicherheit nicht zuverlässig beurteilbar; keine direkten mikrozirkulatorischen Endpunkte gepoolt.
Schlussfolgerung der Autor:innen
Anisodamin als adjuvante Therapie beim septischen Schock könnte die 28-Tage-Mortalität senken und bestimmte hämodynamische, perfusions- und Organfunktionsparameter verbessern. Große multizentrische RCTs sind nötig.
Kernaussagen
- 28-Tage-Mortalität in 6 Studien niedriger: RR 0,76 (95 %-KI 0,62–0,93)
- Bessere MAP, SVRI, Lactat-Clearance und niedrigere SOFA-/APACHE-II-Scores
- Sicherheitsdaten lückenhaft; kardiale Sicherheit unklar
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.10.2026. Verfasst von Yang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The Sixth Affiliated Hospital of Jinan University, Dongguan, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Background
Some patients with septic shock still exhibit microcirculatory dysfunction and impaired tissue oxygen metabolism (macro–micro dissociation), even when macrohemodynamic targets are achieved. Anisodamine may improve patients’ symptoms through multiple mechanisms, including anti-inflammatory and immunomodulatory effects mediated by the cholinergic anti-inflammatory pathway and the relief of microvascular spasm; however, the quality of existing evidence is variable. This study aimed to systematically evaluate the efficacy and safety of anisodamine as adjuvant therapy for septic shock.
Methods
We systematically searched PubMed, the Cochrane Central Register of Controlled Trials, Embase, Web of Science, CNKI, Wanfang Data, and the VIP database from inception to 1 June 2026. RCTs comparing anisodamine with control in septic shock were included. The risk of bias was assessed using the Cochrane risk-of-bias tool, and the certainty of evidence was rated using the GRADE approach.
Results
A total of 14 RCTs (2 in English and 12 in Chinese) were included. Compared with control, anisodamine reduced 28-day mortality (6 studies; RR = 0.76; 95% CI, 0.62–0.93). Anisodamine also significantly increased mean arterial pressure (MD = 3.92; 95% CI, 1.85–5.98) and the systemic vascular resistance index (MD = 74.78; 95% CI, 17.59–131.97). Furthermore, anisodamine increased the Lactate clearance rate (MD = 16.27; 95% CI, 9.26–23.28), reduced serum Lactate (MD = −0.68; 95% CI, −1.10 to −0.26), and increased oxygen consumption (VO 2 ; MD = 23.10; 95% CI, 11.53–34.68) without increasing oxygen delivery (DO 2 ). Anisodamine also reduced the SOFA score (MD = −1.17; 95% CI, −1.95 to −0.39) and the APACHE-II score (MD = −1.50; 95% CI, −2.34 to −0.65), and shortened the duration of vasoactive agent use, ICU length of stay (LOS), and duration of mechanical ventilation, although the total hospital LOS was unchanged. Heart rate was similar between groups based on limited data. However, adverse events were under-reported across studies, and cardiac safety of anisodamine could not be reliably assessed from the available evidence.
Conclusion
Anisodamine as an adjuvant therapy for septic shock may reduce 28-day mortality and improve certain macrocirculatory hemodynamic parameters, tissue perfusion, oxygen metabolism, and organ function indicators. A microcirculatory mechanism is plausible but remains unproven, as no direct microcirculatory endpoint could be pooled. In addition, given that the included studies were mostly small-sample trials with substantial heterogeneity and limited certainty of evidence, large-sample, multicenter RCTs are needed (ideally focusing more on microcirculatory indicators) to further clarify the mechanism, optimal dose, timing, and appropriate treatment population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
- School of Southern Medicine, Guangdong Jiangmen Chinese Medicine College, Jiangmen, China.
- Department of Intensive Care Unit, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
- Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zitieren
APA
Chen, Y., Feng, Y., Zhong, G., Wang, W., Zhou, H., Yuan, S., Guan, L., He, W., Tan, Z., & Yin, W. (2026). Efficacy and safety of anisodamine as adjuvant therapy in septic shock: a systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1976742
Vancouver
Chen Y, Feng Y, Zhong G, Wang W, Zhou H, Yuan S, et al. Efficacy and safety of anisodamine as adjuvant therapy in septic shock: a systematic review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1976742
BibTeX
@article{Chen2026,
author = {Chen, Yang and Feng, Yuxuan and Zhong, Guangyao and Wang, Wei and Zhou, Haixia and Yuan, Shujuan and Guan, Liqing and He, Wei and Tan, Zhenjie and Yin, Weirong},
title = {Efficacy and safety of anisodamine as adjuvant therapy in septic shock: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1976742}
}
EUVIMED